OTCMKTS:NICXF - NicOx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.16 0.00 (0.00 %) (As of 05/22/2019 04:00 PM ET)Previous Close$6.16Today's Range$6.16 - $6.1652-Week Range$5.10 - $10.0150VolumeN/AAverage Volume6 shsMarket Capitalization$182.09 millionP/E RatioN/ADividend YieldN/ABeta1.07 ProfileAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nicox S.A., an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The company's product pipeline includes VyzultaTM, an intraocular pressure-lowering treatment; and NCX 470, a nitric oxide (NO)-donating candidate to treat glaucoma, as well as stand-alone NO donors for specific applications in ophthalmic diseases. It also develops ZERVIATE, an eye drop formulation of cetirizine for allergic conjunctivitis; NCX 4280, an ophthalmic solution that targets morning ocular congestion; and NCX 4251, a patented formulation of fluticasone propionate to treat blepharitis. The company has collaborations with Bausch + Lomb, Astra Zeneca, Merck, Pfizer, and Ironwood Pharmaceuticals, Inc., as well as Novaliq GmbH. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France. Receive NICXF News and Ratings via Email Sign-up to receive the latest news and ratings for NICXF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NICXF Previous SymbolNASDAQ:NICXF CUSIPN/A CIKN/A Webhttp://www.nicox.com/ Phone33-4-97-24-53-00Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales9,104.48 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees31 Outstanding Shares29,560,000Market Cap$182.09 million Next Earnings DateN/A OptionableNot Optionable NicOx (OTCMKTS:NICXF) Frequently Asked Questions What is NicOx's stock symbol? NicOx trades on the OTCMKTS under the ticker symbol "NICXF." What is the consensus analysts' recommendation for NicOx? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NicOx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NicOx. Has NicOx been receiving favorable news coverage? Press coverage about NICXF stock has been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NicOx earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. Who are some of NicOx's key competitors? Some companies that are related to NicOx include Northgate (NGTEF), Orocobre (OROCF), AO World (AOWDF), Zealand Pharma Aktieselskabet (ZLDPF), Oxford BioMedica (OXBDF), Pharma Mar (PHMMF), CONSORT Med PLC/S (CSRMY), OPHIR ENERGY PL/ADR (OPHRY), Carter Bank and Trust (CARE), SUPERDRY PLC/ADR (SEPGY), Pax Global Technology (PXGYF), Pendragon (PDGNF), DATATEC Ltd/ADR (DTTLY), EAGLE POINT CR/COM (ECC) and PREMIER FOODS P/ADR (PRRFY). What other stocks do shareholders of NicOx own? Based on aggregate information from My MarketBeat watchlists, some companies that other NicOx investors own include Aerie Pharmaceuticals (AERI), CGG (CGG), HomeStreet (HMST), Quidel (QDEL), Scorpio Bulkers (SALT), Valero Energy Partners (VLP), Innate Pharma (IPHYF), Synairgen (SNG), Standard Life Aberdeen (SLA) and Rightmove (RMV). Who are NicOx's key executives? NicOx's management team includes the folowing people: Mr. Michele Garufi, Co-Founder, Chairman & CEO (Age 65)Ms. Sandrine Gestin, VP of Fin. (Age 52)Dr. Michael V. W. Bergamini, Chief Scientific Advisor (Age 72)Mrs. Emmanuelle Pierry, Sr. Director of Legal AffairsDr. Gavin Spencer, Exec. VP, Chief Bus. Officer & Head of Corp. Devel. (Age 49) How do I buy shares of NicOx? Shares of NICXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NicOx's stock price today? One share of NICXF stock can currently be purchased for approximately $6.16. How big of a company is NicOx? NicOx has a market capitalization of $182.09 million and generates $20,000.00 in revenue each year. NicOx employs 31 workers across the globe. What is NicOx's official website? The official website for NicOx is http://www.nicox.com/. How can I contact NicOx? NicOx's mailing address is Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex, Valbonne I0, 06560. The company can be reached via phone at 33-4-97-24-53-00. MarketBeat Community Rating for NicOx (OTCMKTS NICXF)Community Ranking: 1.8 out of 5 ()Outperform Votes: 86 (Vote Outperform)Underperform Votes: 151 (Vote Underperform)Total Votes: 237MarketBeat's community ratings are surveys of what our community members think about NicOx and other stocks. Vote "Outperform" if you believe NICXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NICXF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What is Cost of Capital? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.